Boehringer Ingelheim

Boehringer flexes staying power of HER2-mutant lung cancer med

Tyrosine kinase inhibitor zongertinib has an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said.

Zoey Becker Apr 28, 2025 9:00am

Glowing puzzle piece fitting into puzzle

Boehringer slots synthetic lethal program into oncology pipeline

Apr 23, 2025 7:45am

Three blocks displaying from left to right a person a handshake and another person

Boehringer lines up B-cell depletion autoimmune R&D via Cue deal

Apr 15, 2025 4:45am

German program matches lost NIH grants with pharma funders

Apr 7, 2025 10:50am

Boehringer commits $31M to ADC R&D via NBE Therapeutics facility

Apr 3, 2025 5:30am

graphic image of different colored hands shaking

Sotio takes up option on ADCs, Boehringer inks discovery pact

Mar 13, 2025 10:53am